MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tran

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focu

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceu

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasda

CARMEL, Ind. and BURLINGTON, Mass.

Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during th

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year

JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and annou

Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst

MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day t

Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the pri

MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during tr

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT -

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-

MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discov

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq:

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical pr

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 t

MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress

US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stag

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider s

CARMEL, Ind. and BURLINGTON, Mass.

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperfor

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst c

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst c

Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweigh

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises

UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and

Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the pr

Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a S

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst c